[go: up one dir, main page]

NO20080351L - Anvendelse av sanglifehrin i HCV - Google Patents

Anvendelse av sanglifehrin i HCV

Info

Publication number
NO20080351L
NO20080351L NO20080351A NO20080351A NO20080351L NO 20080351 L NO20080351 L NO 20080351L NO 20080351 A NO20080351 A NO 20080351A NO 20080351 A NO20080351 A NO 20080351A NO 20080351 L NO20080351 L NO 20080351L
Authority
NO
Norway
Prior art keywords
songlifehrin
hcv
sanlifehrin
hepatitis
prevention
Prior art date
Application number
NO20080351A
Other languages
English (en)
Norwegian (no)
Inventor
Kaspar Zimmermann
Kai Lin
Beat Weidmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37075234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080351(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20080351L publication Critical patent/NO20080351L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20080351A 2005-06-17 2008-01-16 Anvendelse av sanglifehrin i HCV NO20080351L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69149705P 2005-06-17 2005-06-17
PCT/US2006/023394 WO2006138507A1 (en) 2005-06-17 2006-06-15 Use of sanglifehrin in hcv

Publications (1)

Publication Number Publication Date
NO20080351L true NO20080351L (no) 2008-03-14

Family

ID=37075234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080351A NO20080351L (no) 2005-06-17 2008-01-16 Anvendelse av sanglifehrin i HCV

Country Status (21)

Country Link
US (1) US20090221598A1 (es)
EP (1) EP1893211B1 (es)
JP (1) JP2008546708A (es)
KR (1) KR20080033274A (es)
CN (1) CN101242842A (es)
AR (1) AR054778A1 (es)
AT (1) ATE524183T1 (es)
AU (1) AU2006259348B2 (es)
BR (1) BRPI0613142A2 (es)
CA (1) CA2611151A1 (es)
EC (1) ECSP078029A (es)
GT (1) GT200600262A (es)
MA (1) MA29600B1 (es)
MX (1) MX2007016068A (es)
NO (1) NO20080351L (es)
PE (1) PE20070118A1 (es)
RU (1) RU2427372C2 (es)
TN (1) TNSN07477A1 (es)
TW (1) TW200740438A (es)
WO (1) WO2006138507A1 (es)
ZA (1) ZA200710551B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102224242B (zh) * 2008-09-24 2014-09-24 中国科学院上海有机化学研究所 新基因簇
US20120295346A1 (en) * 2009-07-22 2012-11-22 Tufts University Methods and compositions for modulating membrane potential to influence cell behavior
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
AU2011214135B2 (en) 2010-02-09 2014-07-31 Neurovive Pharmaceutical Ab Sanglifehrin based compounds
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
GB201008123D0 (en) 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
AR084217A1 (es) * 2010-12-10 2013-05-02 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
CN103619336B (zh) * 2010-12-20 2017-10-27 纽洛维弗制药有限公司 Sanglifehrin衍生物及其制备方法
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
WO2012145426A1 (en) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
GB201118334D0 (en) 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
WO2013185103A1 (en) * 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
NZ724616A (en) 2012-06-08 2018-06-29 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
EP1018558A3 (en) 1990-04-06 2002-06-05 Genelabs Technologies, Inc. Hepatitis C Virus Epitopes
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
GB9318612D0 (en) 1993-09-08 1993-10-27 Sandoz Ltd An assay
PT730470E (pt) 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
NZ503263A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
RU2180862C2 (ru) * 1999-11-30 2002-03-27 Научно-исследовательский институт клинической и экспериментальной лимфологии СО РАМН Способ лечения хронических вирусных гепатитов
ATE332693T1 (de) * 2000-03-02 2006-08-15 Sang Geon Kim Pharmazeutische zusammensetzung zur behandlung und vorbeugung von leberzirrhose und leberfibrose
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
DE60105424T2 (de) 2000-05-26 2005-09-22 Idenix (Cayman) Ltd. Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
YU92202A (sh) 2000-05-26 2006-01-16 Idenix (Cayman) Limited Metode i smeše za lečenje flavi virusa i pesti virusa
MY141594A (en) 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
EP1301527A2 (en) 2000-07-21 2003-04-16 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
NZ523781A (en) 2000-07-21 2004-10-29 Corvas Int Inc Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2002018198A1 (en) 2000-08-28 2002-03-07 Roe Jae Ick Generator of two-wheeled vehicle and lighting system thereby
AU2002248147B2 (en) 2000-11-20 2006-04-06 Bristol-Myers Squibb Company Hepatitis C tripeptide inhibitors
HUP0303436A2 (hu) 2000-12-12 2004-01-28 Schering Corp. Diaril-peptidek mint a hepatitis C vírus NS3-szerin proteáz inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2002048157A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
EP1793844B1 (en) * 2004-10-01 2010-12-08 Debiopharm S.A. Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection
AU2005322242B2 (en) * 2004-12-23 2010-02-11 Novartis Ag Compositions for HCV treatment

Also Published As

Publication number Publication date
AR054778A1 (es) 2007-07-18
JP2008546708A (ja) 2008-12-25
CN101242842A (zh) 2008-08-13
ATE524183T1 (de) 2011-09-15
ZA200710551B (en) 2008-11-26
TW200740438A (en) 2007-11-01
ECSP078029A (es) 2008-01-23
WO2006138507A1 (en) 2006-12-28
TNSN07477A1 (en) 2009-03-17
AU2006259348A1 (en) 2006-12-28
MX2007016068A (es) 2008-03-10
GT200600262A (es) 2007-03-28
RU2008100587A (ru) 2009-07-27
AU2006259348B2 (en) 2010-07-22
RU2427372C2 (ru) 2011-08-27
EP1893211A1 (en) 2008-03-05
EP1893211B1 (en) 2011-09-14
PE20070118A1 (es) 2007-02-23
US20090221598A1 (en) 2009-09-03
KR20080033274A (ko) 2008-04-16
MA29600B1 (fr) 2008-07-01
BRPI0613142A2 (pt) 2010-12-21
CA2611151A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
NO20080351L (no) Anvendelse av sanglifehrin i HCV
NO20070751L (no) Inhibitorer av HCV-replifikasjon
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
NO20073105L (no) Pyridazinonforbindelser
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
NO20081086L (no) Makrosykliske peptider som HCV NS3-proteaseinhibitorer
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
EP1924593B8 (en) Hcv ns3 protease inhibitors
WO2006119061A3 (en) Hcv ns3 protease inhibitors
NO20090453L (no) Hepatitt C Virusinhibitorer
MY164469A (en) Hcv ns3 protease inhibitors
WO2007081974A3 (en) Viral hepatitis treatment
ATE474827T1 (de) Hcv-replikationshemmer
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
TW200612898A (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
NO20075616L (no) Tripeptider som hepatitt C virus inhibitorer
WO2008021936A3 (en) Hepatitis c virus inhibitors
NO20090447L (no) Hepatittt C virusinhibitorer
NO20091706L (no) Inhibitorer av hepatitt C virus
WO2007089618A3 (en) Hepatitis c serine protease inhibitors and uses therefor
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
WO2006104945A3 (en) Hepatitis c therapies
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application